Former President & COO Ambaw Bellete Plans $696K Stock Sale, Extending $22.5M Post-Departure Liquidation
CGON has more than doubled off its 52-week low of $23.65.
Summary
Former President & COO Ambaw Bellete plans to sell $696K in CG Oncology shares, adding to $22.5M in sales over the past 3 months, continuing a post-departure liquidation trend.
Key Events · Ownership and Investor Activity · CGON
-
Former President & COO Files to Sell $696K in Stock
Ambaw Bellete, who departed the company on June 30, 2026, filed a Form 144 to sell 9,250 shares acquired via option exercise, valued at approximately $696,062.50 based on recent prices.
-
Adds to $22.5M in Sales Over Past 3 Months
Bellete has already sold 306,741 shares for gross proceeds of $22,483,800.65 since May 2026, indicating a systematic liquidation of his holdings following his departure.
-
Selling Near 52-Week High After Departure
The proposed sale comes with the stock trading near its 52-week high of $77.00, and follows the company's announcement of a $500 million expansion of its at-the-market equity program and a wider Q2 net loss of $79.1 million.
-
Insider Sentiment Concerns
Persistent selling by a recently departed C-suite executive may signal lack of confidence in the company's near-term prospects, especially as pivotal trial data approaches.
Analysis · CGON · Life Sciences
Ambaw Bellete, who stepped down as President & COO effective June 30, 2026, has filed a Form 144 to sell an additional 9,250 shares worth approximately $696,000. This follows $22.5 million in sales over the past three months, signaling a continued liquidation of his holdings after his departure. While the proposed sale is modest relative to the company's $6.6 billion market cap, the pattern of persistent selling by a former top executive near the 52-week high raises concerns about insider sentiment, especially as the company recently expanded its ATM program by $500 million and reported a widening Q2 loss.
At the time of this filing, CGON was trading at $75.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $23.65 to $77.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.